TrialInvestigational new drugs2004

Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.

Samir D Undevia et al.PubMed ↗Publisher ↗

No numbers read from the abstract.